What's Happening?
Arrowhead Pharmaceuticals has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending the approval of REDEMPLO (plozasiran) for reducing triglyceride levels in adults with familial
chylomicronemia syndrome (FCS). This recommendation is based on the successful results of the Phase 3 PALISADE study, which demonstrated significant reductions in triglycerides and a lower incidence of acute pancreatitis among patients treated with REDEMPLO compared to those on placebo. If approved by the European Commission, REDEMPLO would become the first and only small interfering RNA (siRNA) medicine authorized in the EU for both genetically confirmed and clinically diagnosed FCS patients. The drug is already approved in the United States, Canada, and China.
Why It's Important?
The approval of REDEMPLO in Europe would mark a significant advancement in the treatment of FCS, a rare and severe condition characterized by extremely high triglyceride levels, leading to a higher risk of acute pancreatitis and other complications. Current treatment options for FCS are limited, and REDEMPLO offers a new therapeutic approach by targeting the mRNA encoding apolipoprotein C-III, a key regulator of triglyceride metabolism. This development could improve the quality of life for patients with FCS by providing a more effective treatment option. Additionally, the approval would expand Arrowhead Pharmaceuticals' market presence in Europe, potentially increasing access to care for FCS patients and enhancing the company's position in the global pharmaceutical industry.
What's Next?
The European Commission is expected to make a decision on the marketing authorization of REDEMPLO in the second quarter of 2026. If approved, Arrowhead Pharmaceuticals plans to work with regulators and the healthcare community to expedite the availability of REDEMPLO to patients across Europe. The company is also conducting additional Phase 3 studies to further investigate the efficacy of plozasiran in treating severe hypertriglyceridemia, which could lead to broader applications of the drug. The outcome of these studies and the European Commission's decision will be crucial in determining the future market dynamics and availability of REDEMPLO.
